Instituto Nacional de Cardiologia Ignacio Chavez   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Mexico City Mexico (1944)

Organization Overview

First Clinical Trial
2006
NCT00424320
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Instituto Nacional de Cardiología Ignacio Chávez | Instituto Nacional de Cardiologia Ignacio Chavez | Instituto Nacional de Cardiología "Ignacio Chavez" | Instituto Nacional de Cardiología "Ignacio Chávez" | Instituto Nacional de Cardiología Ignacio Chávez

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Coronary Artery Disease (Phase 4)

Fibrosis (Phase 3)

Hypertension (Phase 2)

Hyperuricemia (Phase 3)

Inflammation (Phase 3)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Metabolic Syndrome (Phase 2)

Peritoneal Fibrosis (Phase 3)

Proteinuria (Phase 3)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Syndrome (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial APIs: 28